Access program for crizanlizumab for sickle cell disease
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This program provides crizanlizumab, a medicine that may help reduce pain crises in sickle cell disease, to patients who have no other treatment options and cannot join a clinical trial. It is a special access program for individual patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a serious or life-threatening condition, such as sickle cell disease.
- There is no other satisfactory treatment available for your condition.
- You are not eligible for or cannot participate in a clinical trial.
- Your doctor has requested this medicine for you and believes it may help.
- The medicine is allowed in your country and will not interfere with ongoing studies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called crizanlizumab to see if it helps improve oxygen delivery in people with sickle cell anemia. It may help reduce pain crises and other complications.
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
This study lets people with sickle cell disease who already finished a Novartis crizanlizumab trial continue treatment under a rollover plan. It’s designed for participants who benefited from crizanlizumab and completed the earlier study schedule without major ongoing side effects.
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
This trial studies tocilizumab (a medicine that calms inflammation) to treat acute chest syndrome in people with sickle cell disease. It may help improve symptoms and recovery by targeting key immune signals involved in this complication.
This trial tests if the drug tocilizumab can help treat acute chest syndrome, a serious lung complication of sickle cell disease. It is for people with sickle cell disease who are hospitalized and need oxygen or breathing support. The study compares tocilizumab to a placebo to see if it speeds up recovery.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.